Slyepchenko, Anastasiya
Uher, Rudolf
Ho, Keith
Hassel, Stefanie
Matthews, Craig
Lukus, Patricia K.
Daros, Alexander R.
Minarik, Anna
Placenza, Franca
Li, Qingqin S.
Rotzinger, Susan
Parikh, Sagar V.
Foster, Jane A.
Turecki, Gustavo
Müller, Daniel J.
Taylor, Valerie H.
Quilty, Lena C.
Milev, Roumen
Soares, Claudio N.
Kennedy, Sidney H.
Lam, Raymond W.
Frey, Benicio N.
Funding for this research was provided by:
OBI
Article History
Received: 29 December 2022
Accepted: 5 September 2023
First Online: 15 September 2023
Competing interests
: A.S., A.R.D., B.N.F., L.C.Q., and S.H. have no competing interests to declare. S.H.K. has received funding for Consulting or Speaking engagements from Abbvie, Boehringer-Ingelheim, Janssen, Lundbeck, Lundbeck Institute, Merck, Otsuka Pfizer, Sunovion and Servier. He has received Research Support from Abbott, Brain Canada, CIHR (Canadian Institutes of Health Research), Janssen, Lundbeck, Neurocrine, Ontario Brain Institute, Otsuka, Pfizer, SPOR (Canada's Strategy for Patient-Oriented Research). He holds stock/stock options in Field Trip Health. SR has grant funding from Ontario Brain Institute and holds a patent: Teneurin C-terminal associated peptides (TCAP) and methods and uses thereof.